Renal cancer assembloids reveal a fibroblast–T cell pathway influencing immunotherapy response
Published in Biology, Drugs development & discovery, Immunology, Journals, Tools.
Published October 30, 2026.
A Nature study published October 28 introduces patient-derived renal cancer assembloids that combine tumor cells, cancer-associated fibroblasts and tumor-infiltrating immune cells. The approach lets researchers manipulate individual components while studying their interactions.
The team initially used pretreatment samples from six patients to construct patient-matched models. Combining genetically engineered assembloids with humanized mouse experiments revealed a signaling relationship involving tumor-derived WNT, fibroblast production of activin A and CD8 T cells.
In the experimental systems, this pathway supported a stem-like T-cell state associated with responsiveness to PD-1 blockade. The findings illustrate why fibroblasts can have different effects depending on their interactions with tumor and immune cells.
These assembloids are research models, not validated clinical tests for choosing treatment. The small initial patient sample and limitations of cultures and humanized mice require broader validation. The study does not establish that manipulating activin A safely improves outcomes in patients.